Emily E. Lyons
Impact in
- Cancer Research top 5%
- Cancer Genomics and Diagnostics
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
Papers in
- Oncology 7
- Pancreatic and Hepatic Oncology Research 7
- Peptidase Inhibition and Analysis 1
-
- Cancer Genomics and Diagnostics 5
- Co-authors
- Michael J. Pishvaian (7 shared papers)Andrew Hendifar (6 shared papers)Edik M. Blais (7 shared papers)Emanuel F. Petricoin (5 shared papers)Lola Rahib (4 shared papers)Vincent Chung (5 shared papers)Subha Madhavan (5 shared papers)Davendra Sohal (5 shared papers)
- Journals
- JCO Precision Oncology (2 papers)Journal of Clinical Oncology (2 papers)Clinical Cancer Research (1 paper)The Lancet Oncology (1 paper)Annals of Oncology (1 paper)
- Partner nations
- United States
In The Last Decade
Emily E. Lyons
6 papers receiving 612 citations
Emily E. Lyons's Hit Papers
Peers
Comparison fields: 5 of 38
- Cancer Research 289
- Oncology 487
- Pulmonary and Respiratory Medicine 84
- Pathology and Forensic Medicine 33
- Molecular Biology 113
Countries citing papers authored by Emily E. Lyons
This map shows the geographic impact of Emily E. Lyons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily E. Lyons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily E. Lyons more than expected).
Fields of papers citing papers by Emily E. Lyons
This network shows the impact of papers produced by Emily E. Lyons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily E. Lyons. The network helps show where Emily E. Lyons may publish in the future.
Co-authors
The 25 scholars most cited alongside Emily E. Lyons, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial Hit paper breakdown → | 2020 | 348 |
| 2 | 2018 | 156 | |
| 3 | 2019 | 66 | |
| 4 | 2021 | 22 | |
| 5 | 2019 | 17 | |
| 6 | 2020 | 8 | |
| 7 | 2019 | 0 |
About Emily E. Lyons
Emily E. Lyons is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 7 papers that have together received 617 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (7 papers), Cancer Genomics and Diagnostics (5 papers), Renal cell carcinoma treatment (3 papers), Cancer Mechanisms and Therapy (1 paper), Cancer therapeutics and mechanisms (1 paper), Peptidase Inhibition and Analysis (1 paper) and Lung Cancer Treatments and Mutations (1 paper). The work is most often cited by research in Cancer Research (289 citations), Oncology (487 citations), Pulmonary and Respiratory Medicine (84 citations), Pathology and Forensic Medicine (33 citations) and Molecular Biology (113 citations). Emily E. Lyons has collaborated with scholars based in United States. Frequent co-authors include Michael J. Pishvaian, Andrew Hendifar, Edik M. Blais, Emanuel F. Petricoin, Lola Rahib, Vincent Chung, Subha Madhavan, Davendra Sohal, Lynn M. Matrisian and Jonathan R. Brody. Their work appears in journals such as JCO Precision Oncology, Journal of Clinical Oncology, Clinical Cancer Research, The Lancet Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.